Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Food Effect of Vericiguat Pediatric Formulation
NCT03145038Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Vericiguat oral suspension (Formulation 4) in heart failure (HF) (6 arms), sponsored by Bayer. Primary endpoints: Area Under the Plasma Concentration vs. Time Curve Divided by Dose and Maximum Plasma Concentration Divided by Dose. Started May 2017; status: completed.
02
Drugs
Vericiguat oral suspension (Formulation 4)
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03145038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03145038.